Hyster-Yale Reports Significant Losses in 2025 Amid Economic Challenges
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy HY?
Source: PRnewswire
- Significant Revenue Decline: Hyster-Yale reported total revenues of $3.769 billion for 2025, a 13% decrease year-over-year, primarily due to economic uncertainty dampening customer demand across all product lines.
- Increased Net Loss: The company experienced a net loss of $60.1 million in 2025, a stark contrast to a net income of $142.3 million in 2024, reflecting severe challenges amid high tariffs and weak market demand.
- Operating Profit Plummets: In Q4 2025, operating losses reached $37.2 million, a 215% decline from a profit of $32.3 million in the same quarter of 2024, indicating significant shortcomings in cost management and market adaptability.
- Uncertain Future Outlook: While the company anticipates gradual improvement in bookings for 2026, ongoing tariff policies and market uncertainties are expected to continue exerting pressure on overall financial performance, leading to greater profitability challenges.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HY
Wall Street analysts forecast HY stock price to fall
2 Analyst Rating
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 39.340
Low
33.00
Averages
36.50
High
40.00
Current: 39.340
Low
33.00
Averages
36.50
High
40.00
About HY
Hyster-Yale, Inc. and its subsidiaries, including its operating company, Hyster-Yale Materials Handling, Inc. (HYMH), are a globally integrated company offering application-tailored lift trucks and solutions aimed at meeting the specific materials handling needs of its customers. The Company, through its subsidiary, HYMH, designs, engineers, manufactures, sells, and services a comprehensive line of lift trucks, attachments, aftermarket parts and technology solutions marketed globally primarily under the Hyster and Yale brand names. Its subsidiary, Bolzoni S.p.A. is a producer and distributor of attachments, forks and lift tables marketed under the Bolzoni, Auramo and Meyer brand names. Nuvera Fuel Cells, LLC, is focused on the designing, manufacturing and sale of hydrogen fuel cell stacks and engines. Its solutions include attachments and hydrogen fuel cell power products, telematics, automation and fleet management services, as well as other power options for its lift trucks.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- Earnings Announcement Date: Hyster-Yale Materials Handling is set to announce its Q4 earnings on March 3rd after market close, with a consensus EPS estimate of -$1.23, reflecting a staggering 183.7% year-over-year decline, indicating significant profitability challenges for the company.
- Revenue Decline Forecast: The expected revenue for the quarter is $916.43 million, down 14.4% year-over-year, which highlights weak market demand and the challenges the company faces in a competitive environment, potentially impacting investor confidence moving forward.
- Historical Performance Review: Over the past year, Hyster-Yale has beaten EPS estimates 50% of the time and revenue estimates 75% of the time; however, the current financial outlook suggests the company is under considerable pressure, raising concerns about its future performance.
- Market Analysis Perspective: According to Seeking Alpha's Quant Rating, Hyster-Yale is facing too many challenges to upgrade, indicating that investors should carefully assess the company's growth potential amid these difficulties.
See More
- Significant Order Growth: Q4 2025 bookings surged 42% sequentially and 35% year-over-year, indicating early signs of demand recovery in the Americas, potentially laying the groundwork for future performance rebounds.
- Cash Flow Improvement: Operating cash flow increased to $57 million in Q4, primarily driven by enhanced inventory management efficiency, demonstrating the company's ability to maintain financial flexibility amid economic uncertainty.
- Revenue and Profit Decline: Q4 revenues fell to $923 million, a 14% year-over-year decrease, with an operating loss of $37 million, reflecting the adverse impact of reduced shipment volumes and approximately $40 million in tariff costs on financial performance.
- Cautious 2026 Outlook: Shipment volumes are expected to increase in the second half of 2026, although a small loss may occur in the first half; however, overall operating profit is anticipated to improve, showcasing the company's strategic adjustments in navigating market challenges.
See More
- Disappointing Earnings: Hyster-Yale reported a Q4 non-GAAP EPS of -$2.06, missing expectations by $0.83, indicating significant challenges in profitability that could undermine investor confidence.
- Revenue Decline: The company’s Q4 revenue of $923.2 million represents a 13.7% year-over-year decline, although it exceeded market expectations by $6.77 million, the ongoing revenue drop may affect future liquidity and investment decisions.
- Uncertain Outlook: The implementation of a 10% Chinese tariff in the U.S. by November 2025, along with the expiration of the current Section 301 tariff exemption for lift truck parts in November 2026, will pressure the company’s cost structure and impact its market competitiveness.
- Demand Forecast Dependency: The company’s demand forecasts are based on booking trends, backlog levels, and market data, indicating sensitivity to market dynamics, with successful implementation of proactive initiatives being crucial for future growth recovery.
See More
- Quarterly Financial Performance: Hyster-Yale reported a loss of $52.5 million in Q4, translating to a loss of $2.96 per share, with an adjusted loss of $2.06 per share, indicating significant pressure on the company's market competitiveness and profitability challenges.
- Annual Performance Overview: The company faced an annual loss of $60.1 million, or $3.40 per share, despite generating $3.77 billion in revenue, highlighting ongoing difficulties in cost management and market demand.
- Revenue Analysis: With Q4 revenue at $923.2 million, the relatively high income failed to convert into profit, reflecting an urgent need for the company to enhance operational efficiency and reduce costs.
- Market Outlook: Hyster-Yale's financial results may impact its future investment and expansion plans, prompting investors to closely monitor how the company addresses its current financial challenges to restore profitability.
See More
- Significant Revenue Decline: Hyster-Yale reported total revenues of $3.769 billion for 2025, a 13% decrease year-over-year, primarily due to economic uncertainty dampening customer demand across all product lines.
- Increased Net Loss: The company experienced a net loss of $60.1 million in 2025, a stark contrast to a net income of $142.3 million in 2024, reflecting severe challenges amid high tariffs and weak market demand.
- Operating Profit Plummets: In Q4 2025, operating losses reached $37.2 million, a 215% decline from a profit of $32.3 million in the same quarter of 2024, indicating significant shortcomings in cost management and market adaptability.
- Uncertain Future Outlook: While the company anticipates gradual improvement in bookings for 2026, ongoing tariff policies and market uncertainties are expected to continue exerting pressure on overall financial performance, leading to greater profitability challenges.
See More
- Small-Cap Focus: Congressman Tim Moore has made multiple trades in 2025, including purchasing shares of Genprex, a gene therapy company with a market cap of $5.2 million, indicating a continued interest in small-cap stocks that may influence investor confidence in this sector.
- Significant Trade Amounts: Moore's three purchases of Genprex totaled between $31,000 and $115,000, reflecting his optimism about the company despite its recent poor performance, which could attract the attention of other investors.
- Investment in Simply Good Foods: Moore also bought shares of Simply Good Foods, with investments ranging from $30,000 to $100,000, despite the company's stock price dropping 53% over the past 52 weeks, highlighting the potential for high-risk investments.
- Outstanding Trading Performance: Moore was recognized as the top-performing member of Congress for stock trades in 2025, achieving a 52% return that significantly outperformed the S&P 500's 16.6% gain, which may draw more investors to his trading strategies.
See More










